PHENTERMINE AND NICOTINE FOR SMOKING CESSATION

拟议的研究将描述急性和慢性影响， 芬特明，一种多巴胺释放剂，芬氟拉明，一种血清素 单用和联合用药对吸烟反应的影响 戒断症状和120名妇女戒烟后体重增加。 芬特明和芬氟拉明联合给药时， 已被证明可促进肥胖患者的体重减轻， 表明它们也可以减少对酒精和可卡因渴望。 因此，这种药物组合也可以有效地减少药物依赖性。 体重增加和渴望经历的吸烟者试图 戒烟，五月吸烟复吸的主要原因是症状 个体 拟议的研究将评估 芬特明和芬氟拉明对主观、生理和认知的影响 吸烟的影响，以及吸烟戒断症状， 女性担心戒烟期间体重增加。 科目 将被随机分配接受芬特明，芬氟拉明， 芬特明=芬氟拉明或安慰剂，在一次实验室检查期间 然后进行为期六周的临床试验 在实验室会议期间， 受试者将接受单次急性剂量的治疗药物， 双盲条件下，将吸烟含尼古丁和脱- 尼古丁香烟 主观、生理和认知影响 每种香烟的吸烟量都将被测量。 在双盲 在临床阶段，受试者将接受6周的治疗， 无论他们在实验室会议期间接受何种药物。 吸烟 戒断、戒断症状、体重增加和生理指标 将在6周治疗期间每周评估一次，并且 分别在一个月三个月和六个月后 受试者将接受简短的 戒烟、饮食和锻炼的咨询和支持 临床试验期间的每次实验室访视。 在下面- 随访、吸烟状况、戒断症状和体重将 监测。 这项研究的结果将有助于 了解香烟背后的神经化学机制 吸烟和戒烟，并可能提供一个新的和有效的 戒烟治疗。

The proposed research will characterize the acute and chronic effects of phentermine, a dopamine releaser, and fenfluramine, a serotonin releaser, alone and in combination, on responses to smoking, smoking withdrawal symptoms, and post-cessation weight gain in 120 women. Phentermine and fenfluramine, when administered in combination, have been shown to promote weight loss in obese patients and clinical reports indicate that they may also reduce craving for alcohol and cocaine. Thus, this drug combination may also be efficacious in reducing the weight gain and craving experienced by cigarette smokers attempting to quit, symptoms which are major contributors to smoking relapse in may individuals. The proposed study will evaluate the effects of phentermine and fenfluramine on subjective, physiologic and cognitive effects of smoking, as well as on symptoms of smoking withdrawal in women concerned about weight gain during smoking cessation. Subjects will be randomly assigned to receive either phentermine, fenfluramine, phentermine = fenfluramine, or placebo during one laboratory session followed by a six week clinical trial. During the laboratory session, subjects will receive a single acute dose of the treatment drug under double-blind conditions, and will smoke a nicotine-containing and de- nicotinized cigarette. Subjective, physiologic and cognitive effects of smoking each type of cigarette will be measured. In the double-blind clinical phase, subjects will receive six weeks of treatment with whichever drug they received during the laboratory sessions. Smoking abstinence, withdrawal symptoms, weight gain, and physiologic measures will be assessed at weekly intervals during six weeks of treatment, and at one, three, and six months thereafter. Subjects will receive brief counseling and support for smoking cessation, diet and exercise during each of the laboratory visits during the clinical trial. At the follow- up visits, smoking status, withdrawal symptoms, and weight will be monitored. The results of this study will contribute to the understanding of the neurochemical mechanisms underlying cigarette smoking and smoking cessation, and may provide a new and efficacious treatment for smoking cessation.